Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea

被引:0
作者
Motoko Ida
Akito Nishida
Hiraku Akiho
Yoshihiro Nakashima
Kei Matsueda
Shin Fukudo
机构
[1] Astellas Pharma Inc.,Japan
[2] Astellas Pharma Inc.,Asia Planning & Administration, Medical & Development
[3] Astellas Pharma Inc.,Development Project Management
[4] Astellas Pharma Inc.,Japan
[5] Sakura Life Clinic,Asia Clinical Development 2, Development
[6] Tohoku University Graduate School of Medicine,Japan
来源
BioPsychoSocial Medicine | / 11卷
关键词
5-hydroxytryptamine (5-HT); Abdominal pain; Abdominal discomfort; Global improvement; Stool consistency; Irritable bowel syndrome severity index;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 125 条
[1]  
Drossman DA(2006)The functional gastrointestinal disorders and the Rome III process Gastroenterology 130 1377-1390
[2]  
Longstreth GF(2006)Functional bowel disorders Gastroenterology 130 1480-1491
[3]  
Thompson WG(2008)Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits Am J Gastroenterol 103 2550-2561
[4]  
Chey WD(2005)Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome Clin Gastroenterol Hepatol 3 349-357
[5]  
Houghton LA(1998)Involvement of the 5-HT Am J Physiol 274 G827-G831
[6]  
Mearin F(1996) receptor in CRH-induced defecation in rats Digestion 57 478-483
[7]  
Spiller RC(1998)Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT Aliment Pharmacol Ther 12 849-855
[8]  
Kanazawa M(1991) antagonism (Ondansetron) J Pharmacol Exp Ther 259 15-21
[9]  
Palsson OS(1992)Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome J Pharmacol Exp Ther 261 297-303
[10]  
Thiwan SO(1995)Pharmacologic profile of (R)-5-[(1-methyl-3-indolyl)carbonyl]-4,5,6,7-tetrahydro-1H-benzimidazole hydrochloride (YM060), a potent and selective 5-hydroxytryptamine3 receptor antagonist, and its enantiomer in the isolated tissue Jpn J Pharmacol 69 205-214